EUVIMEDEUVIMED entdecken
Crossref

A 177Lu-labeled Inetetamab theranostic conjugate with dual cytotoxic and stromal-depleting activities for targeted radionuclide therapy of HER2-positive breast cancer

Jianping Zheng, Yu Zhang, Qingqing Li, Boyu Cai, Yan Zheng, Qiao Chen, Xiao Li, Shuai Xue, Wenxin Chen, Zhenhua Liu

Bioorganic Chemistry · 2026-11 · 183 · 110616

DOI: 10.1016/j.bioorg.2026.110616 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026-11. Verfasst von Jianping Zheng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provi…. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Breast Neoplasms, Lutetium, Radioisotopes. Die Arbeit nennt 53 Literaturangaben. Gefördert von: Science and Technology Projects of Fujian Province, Bethune Charitable Foundation, Shanghai Pudong New Area Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: HER2-positive breast cancer requires targeted therapies that overcome resistance and desmoplastic barriers. This study aimed to develop and biologically evaluate a 177Lu-labeled Inetetamab conjugate (177Lu-Inetetamab) with dual cytotoxic and stromal-depleting activities for targeted radionuclide therapy. METHODS: 177Lu-Inetetamab was synthesized using p-SCN-Bn-DOTA as the bifunctional chelator. Radiochemical purity, stability, and HER2-specific binding were assessed in vitro. In vivo SPECT/CT imaging, biodistribution, and therapeutic efficacy were evaluated in BT-474 xenograft-bearing mice. Tumor growth, survival, immunohistochemistry (Ki67, BCL-2, γ-H2AX, TNF-α), stromal remodeling (99mTc-FAPI-04 SPECT/CT, Masson's trichrome), and transcriptomic profiling were performed. RESULTS: 177Lu-Inetetamab was successfully synthesized using p-SCN-Bn-DOTA as the bifunctional chelator, achieving a conjugation efficiency of 40.3 ± 2.5% at pH 9.0 and a chelate-to-antibody ratio of approximately 3.3 DOTA per antibody. The radiochemical purity (> 95%) was confirmed by radio-HPLC and radio-TLC and remained stable in PBS and mouse serum at 37 °C for up to 168 h. HER2-specific cellular uptake was confirmed, with an immunoreactive fraction of 75.5 ± 1.9% and a dissociation constant (KD) of 0.772 nM. SPECT/CT showed sustained tumor retention (1.45 ± 0.96 %ID/mL at 168 h) and favorable hepatobiliary clearance. Treatment with 177Lu-Inetetamab significantly suppressed tumor growth (no net growth by day 10, whereas control tumors increased by >150%) and prolonged survival compared to controls. IHC revealed reduced Ki67 and BCL-2, increased γ-H2AX and TNF-α. The reduced FAPI-04 uptake (1.05 ± 0.33 vs. 2.35 ± 0.45%ID/mL) and Masson's staining indicated CAF loss, to which β-emission cross-fire may have contributed. Transcriptomics showed activation of p53-mediated apoptosis and downregulation of profibrotic genes (TGFB2, CCN2, FN1). CONCLUSION: 177Lu-Inetetamab exhibits high HER2 specificity, potent antitumor efficacy, and stromal-modulating activity, supporting its potential as a theranostic agent for resistant or stroma-rich HER2-positive breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesBreast NeoplasmsLutetiumRadioisotopesAntineoplastic AgentsRadiopharmaceuticalsTheranostic NanomedicineAnimalsFemaleHumansMiceTissue DistributionCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorMolecular StructureStructure-Activity RelationshipDose-Response Relationship, DrugMice, NudeSingle Photon Emission Computed Tomography Computed Tomography

Stichwörter der Autor:innen

(177)Lu-labeled proteinHER2SPECT/CTStromal remodelingTargeted radionuclide therapyTumor microenvironment

Substanzen

Erb-b2 Receptor Tyrosine KinasesLutetiumRadioisotopesAntineoplastic AgentsLutetium-177ERBB2 protein, humanRadiopharmaceuticals

Autor:innen und Institutionen

  • Department of Oncology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, 350001, China.
  • Department of Nuclear Medicine, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, 350001, China.
  • School of Chinese Ethnic Medicine, Guizhou Minzu University, Guiyang, 550025, China; Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, 201800, China.
  • Department of ORL-HNS, Shanghai Fourth People's Hospital Affiliated to Tongji University School of Medicine, Shanghai, 200434, China.
  • Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, 201800, China; Department of Nuclear Medicine, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, 201399, China.
  • Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, 201800, China; Department of Nuclear Medicine, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, 201399, China. Ele…

Förderung

  • Science and Technology Projects of Fujian Province
  • Bethune Charitable Foundation
  • Shanghai Pudong New Area Health Commission
  • Chinese Academy of Sciences
  • Natural Science Foundation of Fujian Province

Zitieren

APA

Zheng, J., Zhang, Y., Li, Q., Cai, B., Zheng, Y., Chen, Q., Li, X., Xue, S., Chen, W., & Liu, Z. (2026). A 177Lu-labeled Inetetamab theranostic conjugate with dual cytotoxic and stromal-depleting activities for targeted radionuclide therapy of HER2-positive breast cancer. Bioorganic Chemistry, 183, 110616. https://doi.org/10.1016/j.bioorg.2026.110616

Vancouver

Zheng J, Zhang Y, Li Q, Cai B, Zheng Y, Chen Q, et al. A 177Lu-labeled Inetetamab theranostic conjugate with dual cytotoxic and stromal-depleting activities for targeted radionuclide therapy of HER2-positive breast cancer. Bioorganic Chemistry. 2026;183:110616. doi:10.1016/j.bioorg.2026.110616

BibTeX
@article{Zheng2026,
  author = {Zheng, Jianping and Zhang, Yu and Li, Qingqing and Cai, Boyu and Zheng, Yan and Chen, Qiao and Li, Xiao and Xue, Shuai and Chen, Wenxin and Liu, Zhenhua},
  title = {A 177Lu-labeled Inetetamab theranostic conjugate with dual cytotoxic and stromal-depleting activities for targeted radionuclide therapy of HER2-positive breast cancer},
  journal = {Bioorganic Chemistry},
  year = {2026},
  volume = {183},
  pages = {110616},
  doi = {10.1016/j.bioorg.2026.110616}
}
Kostenlos starten →